Based on our results, we propose a combination regimen using a ZEB1 antagonist as an adjuvant along with simultaneous blockade of the CD47-SIRPα immune checkpoint, which may improve the outcomes of the majority of patients with CSCC in part by disinhibiting innate immunity. This evidence concerns the gene SIRPA and skin squamous cell carcinoma.